PICKERING, ON, May 2, 2018 – Melanie Milburn is appointed Vice President Marketing after successfully undertaking various initiatives and positions in the Purdue Pharma (Canada) commercial organization since 2014.
Melanie has more than 20 years of experience in the commercial operations of Canada’s research-based pharmaceutical companies. She is passionate about helping others grow and develop in their careers.
“It is exciting to recognize Melanie’s leadership and contributions through this promotion,” said David Pidduck, President & CEO. “I look forward to supporting Melanie and her team as they continue to enter new channels and new therapeutic areas while also ensuring our ongoing focus on increasing healthcare professionals’ awareness of The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain.”
Melanie is responsible for the strategic commercialization of our portfolio of approved prescription treatments for ADHD, chemotherapy-induced nausea and vomiting (CINV), various ophthalmic conditions and pain. Through a research and evidence driven approach, Melanie oversees the market research and development of materials & programs that continue to promote our products in line with Health Canada approved product monographs and in compliance with all relevant rules, regulations and codes.
“We support a guidelines-based approach to treating diseases and conditions that may or may not include available pharmaceutical treatments in combination with other approaches,” said Melanie. “It is our responsibility to deliver innovative marketing solutions and information about our approved products — including adverse events and risks – in a way that allows healthcare professionals to make the best decisions for their patients.”
Melanie holds a Bachelor of Science majoring in Applied Health Research from Waterloo University, and is a member of Lean In Canada.
About Purdue Pharma (Canada)
Purdue Pharma (Canada) is a research-based pharmaceutical and consumer healthcare company which has operated in Canada for over 60 years. Its 400 employees are committed to improving the health and quality of life of Canadians. The company has a broad portfolio of prescription and non-prescription medications including: prescription treatments for pain, ADHD, chemotherapy-induced nausea and vomiting (CINV), various ophthalmic conditions and Consumer Healthcare products. The company supports evidence-based education for the safe use of its products. Its headquarters, located in Pickering, ON, include integrated research & development, formulation and manufacturing operations. Privately held and founded by physicians, Purdue Pharma (Canada) is independently associated with the worldwide Purdue/Napp/Mundipharma network of companies. Learn more at www.purdue.ca
Sarah L. Robertson,
Director of Communications,
Purdue Pharma (Canada),